I-Mab Biopharma Signs Licensing Agreement for HyLeukin with Genexine. HyLeukin is an immuno-oncology agent comprised of an optimally engineered Interleukin-7 (IL-7) molecule based on Genexine’s proprietary long-acting platform technology.
Genexine is a leading biotherapeutics company focused on immuno-oncology and orphan disease. Genexine has robust pipelines in clinical and pre-clinical stages based on long-acting Fc fusion technology and therapeutic DNA technology
HyLeukin designed to reconstitute and enhance anti-tumoral Tcell immunity. It consists of an optimally engineered Interleukin-7 (IL-7) molecule biologically fused with the Genexine’s proprietary long-acting platform technology, hybrid Fc (hyFc). HyLeukin is under co-development with Neo Immune Tech (NIT), a US-based spin-off company of Genexine. Genexine recently completed Phase I trial in Korea and based on the current results, HyLeukin demonstrated it was safe and well tolerated in healthy volunteers.
Genexine will establish a joint development committee with I-Mab to pursue global commercialization and new drug development of multi-target antibody-based candidates in immuno-oncology areas.
“We believe this licensing partnership with I-Mab represents an important step in executing Genexine’s immuno-oncology development and will become a criterion of value determination in future global licensing deals“, said Dr. Young Chul Sung, the founder and CTO of Genexine.
“We are very excited to have brought our partnership with Genexine to a new level. This is a highlight of many on-going projects we have been collaborating with”, said Jingwu Zang, founder and CEO of I-Mab Biopharma.
I-Mab is a dynamic and fast-growing global player committed to developing innovative biologics in the areas of immuno-oncology and immuno-inflammation through internal R&D capabilities and global partnerships.